Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 4/20 | 0.33 |
| ▸ | RAB9A | P51151 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GLS | O94925 | 1/20 | 0.31 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10285896 | 0.79 | SMN1; SMN2 (0.43) | SMN1; SMN2MEN1CYP1A2KMT2ACYP3A4 | |
| SCHEMBL19370115 | 0.77 | CA1 (0.40) | SMN1; SMN2MEN1CYP1A2KMT2ACYP3A4 | |
| SCHEMBL2540881 | 0.77 | MEN1 (0.38) | SMN1; SMN2MEN1CYP1A2KMT2ACYP3A4 | |
| SCHEMBL12503454 | 0.76 | KMT2A (0.41) | SMN1; SMN2MEN1CYP1A2KMT2ACA1 | |
| SCHEMBL22966747 | 0.75 | GSR (0.39) | SMN1; SMN2MEN1CYP1A2KMT2ACYP3A4 | |
| SCHEMBL8770450 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL3710557 | 0.72 | CA1 (0.37) | SMN1; SMN2MEN1CYP1A2KMT2ACYP3A4 | |
| SCHEMBL13855709 | 0.71 | CYP1A2 (0.42) | SMN1; SMN2MEN1CYP1A2KMT2ACYP3A4 | |
| SCHEMBL15939753 | 0.71 | SMN1; SMN2 (0.45) | SMN1; SMN2MEN1CYP1A2KMT2ACYP3A4 | |
| SCHEMBL22966587 | 0.70 | SMN1; SMN2 (0.37) | SMN1; SMN2MEN1CYP1A2KMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023134629-A1 | NUCLEAR TRANSPORT REGULATOR AND USE THEREOF | 上海海雁医药科技有限公司 | 2023-07-20 | — | — | WO | disclosed |
| EP-2430006-B1 | CYCLOPENTA[C]PYRROLE-2-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-11-26 | — | — | EP | disclosed |
| US-8697883-B2 | Cyclopenta[C]pyrrole-2-carboxylate derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-04-15 | — | — | US | disclosed |
| US-20120095040-A1 | CYCLOPENTA[C]PYRROLE-2-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-04-19 | — | — | US | disclosed |
| EP-2430006-A1 | CYCLOPENTA[C]PYRROLE-2-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010130944-A1 | CYCLOPENTA[C]PYRROLE-2-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-11-18 | — | — | WO | disclosed |
| US-20090118296-A1 | Heteroaromatic Compounds As Inhibitors Of Stearoyl-Coenzyme A Delta-9 Desaturase | MERCK FROSST CANADA LTD. (CA) | 2009-05-07 | — | — | US | disclosed |
| US-20090118296-A1 | Heteroaromatic Compounds As Inhibitors Of Stearoyl-Coenzyme A Delta-9 Desaturase | MERCK FROSST CANADA LTD. (CA) | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118296-A1 | Heteroaromatic Compounds As Inhibitors Of Stearoyl-Coenzyme A Delta-9 Desaturase | SCD, SCD5, SREBF1 | SMN1; SMN2 2794/4885MEN1 4613/4885CYP1A2 381/4885 |
| US-20120095040-A1 | CYCLOPENTA[C]PYRROLE-2-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | EPOR, ACAD9, CBR1 | SMN1; SMN2 2003/4885MEN1 1554/4885CYP1A2 1188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.